Table 1.
Demographic and clinical characteristics of patients treated with ceftaroline.
| Variable | No. of Patients a | % | 95% CI |
|---|---|---|---|
| Demographic Variables | |||
| Age in years, Median (IQR) | 66 (57–76) | 63–69 | |
| Male Gender | 144/200 | 72 | 65–78 |
| Medical History | |||
| Charlson Score, Median (IQR) | 3 (2–5) | 3–3 | |
| Solid Organ Transplant | 1/200 | 1 | 0–3 |
| Hematopoietic Stem Cell Transplantation | 1/200 | 1 | 0–3 |
| Previous Isolation of MSSA | 6/200 | 3 | 1–6 |
| Previous Isolation of MRSA | 5/200 | 3 | 1–6 |
| Previous Therapy with Ceftaroline | 2/200 | 1 | 0–4 |
| Previous Therapy with Daptomycin | 6/200 | 3 | 1–6 |
| Previous Therapy with Glycopeptides | 5/200 | 3 | 1–6 |
| Previous Therapy with Linezolid | 6/200 | 3 | 1–6 |
| Cross-sectional Variables b | |||
| Length of Hospital Stay in Days, Median (IQR) | 1 (1–3) | 1–2 | |
| Ward of Staying | |||
| ICU | 34/200 | 17 | 12–23 |
| Medical Ward | 155/200 | 78 | 71–83 |
| Surgical Ward | 2/200 | 1 | 0–4 |
| Emergency Department | 9/200 | 5 | 2–8 |
| Presence of CVC c | 13/200 | 7 | 4–11 |
| Presence of Urinary Catheter c | 36/200 | 18 | 13–24 |
| Mechanical Ventilation c | 8/200 | 4 | 2–8 |
| COVID-19 | 165/200 | 83 | 77–87 |
| Neutropenia (ANC < 500/mm3) | 1/200 | 1 | 0–3 |
| Serum Albumin in g/dl d, Median (IQR) | 3.0 (2.5–3.4) | 2.9–3.1 | |
| Missing (serum Albumin not tested) | 56/200 | ||
| Serum Creatinine in mg/dl d, Median (IQR) | 0.9 (0.8–1.2) | 0.9–1.0 | |
| KDIGO Stage of AKI | |||
| No AKI | 170/200 | 85 | 79–89 |
| Stage 1 | 16/200 | 8 | 5–13 |
| Stage 2 Stage 3 |
8/200 6/200 |
4 3 |
2–8 1–6 |
| SOFA Score, Median (IQR) | 2 (2–4) | 2–3 | |
| Septic Shock | 54/200 | 27 | 21–34 |
AKI, acute kidney injury; ANC, absolute neutrophil count; BSI, bloodstream infection; CAP, community-acquired pneumonia; CI, confidence intervals; CVC, central venous catheter; ICU, intensive care unit; IQR, interquartile range; KDIGO, Kidney Disease: Improving Global Outcomes; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; SOFA, sequential organ failure assessment. a Results are presented as No. of patients/Total of patients unless otherwise indicated; b At the time of ceftaroline initiation; c From at least 48 h; d Last measured value before ceftaroline initiation.